Enfanos Announces Agreement with Waters to Advance Mass Spectrometry Solutions for Newborn Screening Research and Applications
- zmherbst
- Nov 12, 2025
- 2 min read
Enfanos Announces Agreement with Waters to Advance Mass Spectrometry Solutions for Newborn Screening Research and Applications
Agreement underscores Enfanos’ dedication to advancing scientific discovery and supporting the newborn screening community.
Enfanos announced a co-marketing agreement with Waters Corporation, a global leader in mass spectrometry technologies. This agreement enables Enfanos to seamlessly connect innovative enzyme activity and biomarker assay products, such as the Enfanos 10-Plex RUO kit and GAG EndoNRE™ biomarkers, with Waters mass spectrometry products, service, and technical support.
“Our goal is to help more newborn screening labs discover and deploy the analytical performance and multiplexing power of mass spectrometry for inborn errors of metabolism (IEM) research and diagnostics development,” notes Hamid Khaledi, CEO, Enfanos. “Enfanos’ industry-leading expertise in enzyme activity and biomarker assay development requires top-tier hardware platforms to provide the most robust analytical methodologies. The Waters portfolio, with products like the Xevo™ TQ-S micro IVD Mass Spectrometer, which is compact, effortlessly maintained, and sensitive enough to cover a wide variety of critical analytes, is a perfect complement to our current solutions and future roadmap.”
“Waters is pleased to work with Enfanos to provide more comprehensive solutions for our newborn screening customers,” states Andy Qiu, Vice President, Clinical Commercial, Waters Corporation. “Our recently launched AA/AC RUO solution includes the analytes guanidinoacetate and creatine, which, combined with our sample preparation approach, delivers improved efficiencies for our customers. Enfanos’ innovative one-punch sample preparation solution for lysosomal storage disorder analytes offers similar benefits. Working together, we can offer holistic, distinctive technologies which streamline workflows for our users and the clinicians they serve.”
Enfanos and Waters will deliver educational materials, technical documentation, marketing materials, and joint demonstrations across portfolios, highlighting how these technologies can be applied in research supporting newborn screening and diagnostics for lysosomal storage disorders (LSDs) and other IEMs. Through coordinated outreach and cross-training of technical teams, Enfanos aims to help laboratories explore optimized workflows for high-quality, reproducible results using mass spectrometry-based approaches.
About Enfanos
Based in Seattle, WA, Enfanos specializes in developing reagents and methodologies for enzyme and metabolite assays. Enfanos was founded in 2018 as GelbChem by scientists from the laboratory of Professor Michael Gelb at the University of Washington. Professor Gelb’s laboratory has been a leading force in the development of new technologies in newborn screening and diagnosis of IEMs for over 20 years. Enfanos is making these methodologies accessible to researchers across the globe.
# # #
Contact:
Zackary (Ari) M. Herbst
Chief Science Officer, Enfanos
For research use only. Not for use in diagnostic procedures
Waters and Xevo are trademarks of Waters Technologies Corporation.
Comments